Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.43
RTRX's Cash to Debt is ranked lower than
57% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. RTRX: 1.43 )
Ranked among companies with meaningful Cash to Debt only.
RTRX' s 10-Year Cash to Debt Range
Min: 0.13  Med: 9999.00 Max: No Debt
Current: 1.43
Equity to Asset 0.41
RTRX's Equity to Asset is ranked lower than
79% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RTRX: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
RTRX' s 10-Year Equity to Asset Range
Min: -3.16  Med: -0.28 Max: 0.41
Current: 0.41
-3.16
0.41
F-Score: 3
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -58.94
RTRX's Operating margin (%) is ranked lower than
88% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. RTRX: -58.94 )
Ranked among companies with meaningful Operating margin (%) only.
RTRX' s 10-Year Operating margin (%) Range
Min: 353.41  Med: 1229.22 Max: 2105.03
Current: -58.94
353.41
2105.03
Net-margin (%) -0.90
RTRX's Net-margin (%) is ranked lower than
74% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. RTRX: -0.90 )
Ranked among companies with meaningful Net-margin (%) only.
RTRX' s 10-Year Net-margin (%) Range
Min: 354.18  Med: 1206.78 Max: 2059.37
Current: -0.9
354.18
2059.37
ROE (%) -3.78
RTRX's ROE (%) is ranked lower than
74% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. RTRX: -3.78 )
Ranked among companies with meaningful ROE (%) only.
RTRX' s 10-Year ROE (%) Range
Min: 0  Med: 0.00 Max: 0
Current: -3.78
ROA (%) -0.35
RTRX's ROA (%) is ranked lower than
69% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. RTRX: -0.35 )
Ranked among companies with meaningful ROA (%) only.
RTRX' s 10-Year ROA (%) Range
Min: -375  Med: -337.76 Max: -142.26
Current: -0.35
-375
-142.26
ROC (Joel Greenblatt) (%) -7959.29
RTRX's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. RTRX: -7959.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RTRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54407.87  Med: -41414.21 Max: -28420.55
Current: -7959.29
-54407.87
-28420.55
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RTRX Guru Trades in

RTRX Guru Trades in

Q1 2014

RTRX Guru Trades in Q1 2014

Steven Cohen 3,932 sh (New)
Steven Cohen 1,291,474 sh (New)
» More
2014

RTRX Guru Trades in 2014

Steven Cohen 307,490 sh (-76.19%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 36.36
RTRX's Forward P/E is ranked lower than
72% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. RTRX: 36.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.71
RTRX's P/B is ranked lower than
73% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. RTRX: 6.71 )
Ranked among companies with meaningful P/B only.
RTRX' s 10-Year P/B Range
Min: 3.05  Med: 4.97 Max: 6.94
Current: 6.71
3.05
6.94
P/S 11.89
RTRX's P/S is ranked lower than
83% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. RTRX: 11.89 )
Ranked among companies with meaningful P/S only.
RTRX' s 10-Year P/S Range
Min: 5.7  Med: 9.28 Max: 12.97
Current: 11.89
5.7
12.97
Days Sales Outstanding 40.65
RTRX's Days Sales Outstanding is ranked higher than
78% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. RTRX: 40.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
RTRX' s 10-Year Days Sales Outstanding Range
Min: 0  Med: 0.00 Max: 0
Current: 40.65

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.35
RTRX's Price/Median PS Value is ranked lower than
51% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. RTRX: 1.35 )
Ranked among companies with meaningful Price/Median PS Value only.
RTRX' s 10-Year Price/Median PS Value Range
Min: 1  Med: 1.00 Max: 1
Current: 1.35
Earnings Yield (Greenblatt) (%) -3.95
RTRX's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. RTRX: -3.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -36.5  Med: 0.00 Max: 0
Current: -3.95
-36.5
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:17R.Germany,
Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Retrophin, Inc. Nov 28 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. Oct 24 2014 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 

More From Other Websites
10 Best Biotech Stocks in the NASDAQ Jul 01 2015
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary Jun 25 2015
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks Jun 24 2015
RETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Jun 11 2015
RETROPHIN, INC. Files SEC form 8-K, Other Events Jun 08 2015
Retrophin Receives Fast Track Designation for RE-024 for the Treatment of Pantothenate... Jun 04 2015
Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog May 28 2015
Retrophin Sells FDA Voucher to Sanofi May 27 2015
RETROPHIN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... May 27 2015
Retrophin Agrees to Sell Priority Review Voucher to Sanofi May 27 2015
Retrophin Agrees to Sell Priority Review Voucher to Sanofi May 27 2015
Retrophin to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
Retrophin to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
RETROPHIN, INC. Financials May 19 2015
Coverage initiated on Retrophin by Avondale May 15 2015
10-Q for Retrophin Inc May 13 2015
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 12 2015
Retrophin posts 1Q profit May 11 2015
Retrophin posts 1Q profit May 11 2015
RETROPHIN, INC. Files SEC form 10-Q, Quarterly Report May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK